認知症の治療の進歩

抄録

Perhaps the most significant topic in 2022 concerning the treatment of dementia was the report at the Clinical Trials on Alzheimer's Disease (CTAD) conference at the end of November of that year that lecanemab had shown favorable effects in early Alzheimer disease (AD). Based on these results, the drug received expedited approval from the U.S. Food and Drug Administration (FDA) on January 6, 2023. Against this backdrop, expectations for the development of disease–modifying drugs for various neurodegenerative diseases, including AD, are increasing. In the field of dementia, in addition to agents targeting amyloid, a number of agents are in development that target the causative proteins of each neurodegenerative disease, including agents targeting tau and α–synuclein. In this article, we will follow suit, organizing by causative protein and drug lineage, and pick up on the results of relatively large clinical studies that have been newly reported in 2022, as well as on clinical studies that have moved forward.